Ramucirumab injection

Brand name: Cyramza

Cyramza Ramucirumab 100 Mg 10 Ml Injection at Rs 70000/vial | Anti Cancer  Medicine in Nagpur | ID: 26420248255

Use in Cancer Treatment

Ramucirumab is for usage alone or in combination with other medications to treat:

  • Colorectal cancer has spread to other parts of the body. It is usually in combination with FOLFIRI to patients whose cancer has progressed during or after therapy with bevacizumab, oxaliplatin, and fluoropyrimidine.
  • A hepatocellular carcinoma is a form of cancer that affects the liver (a type of liver cancer). It is used alone in individuals who have a high level of alpha-fetoprotein in their blood and have previously had sorafenib tosylate treatment.
  • Non-small cell lung cancer has spread to other parts of the body.
  • In individuals with specific mutations in the EGFR gene, erlotinib hydrochloride can be a first-line treatment.
  • Docetaxel is for patients whose illness has worsened during or after platinum chemotherapy. Ramucirumab for individuals whose condition is due to a mutation in the EGFR or ALK genes, and their disease has worsened despite treatment with FDA-approved therapy for these mutations.
  • Advanced or metastatic stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare form of esophageal cancer) (spread to other parts of the body). It is for people whose cancer has become worse after receiving fluoropyrimidine or platinum chemotherapy. It can be alone or in combination with paclitaxel.

Ramucirumab is also under research for use in the treatment of other kinds of cancer.


Anti-angiogenesis activity of a recombinant, completely human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2). Ramucirumab binds to and inhibits VEGFR-2, which may lead to a reduction in tumor nutrition supply and suppression of tumor angiogenesis. Endothelial cells express VEGFR-2, a pro-angiogenic growth factor receptor tyrosine kinase.

Ramucirumab information on MedlinePlus – A summary of key facts regarding this medicine in layman’s terms, which may contain the following:

  • Cautions about this medicine
  • What is the use and how?
  • Whom should you consult before taking it?
  • What you should know about it before using it?
  • Other drugs that might interact with it
  • Possible negative effects

Drugs are frequently under research to see whether they can assist treat or prevent conditions other than those already prevalent. This patient information leaflet covers uses which have been under authorization. Much of the material, though, might also apply to authorized uses that are being investigated.